Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development.

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and Astellas’ Xtandi (enzalutamide) in patients with metastatic castration-sensitive ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...

It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...

Hospitals engaging in industry partnerships were found to be up to 2.5 times more likely to follow NICE guidelines Research commissioned by the Association of the British Pharmaceutical Industry (ABPI ...